FDA Wants Your Thoughts on Medical Device Paperwork—Again
Published Date: 2/26/2026
Notice
Summary
The FDA is asking for public feedback on their plan to keep collecting info about investigational medical devices—those being tested for safety and effectiveness. This affects companies and researchers working on new medical devices, with no new costs or big changes, just a routine paperwork update. Comments are open until March 30, 2026, so now’s the time to speak up!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Overall Paperwork Burden Increased
FDA estimates the total annual paperwork burden for investigational device exemptions increased by 9,919 hours and by 1,033 responses. The agency reports totals of 6,552 annual reporting responses (63,828 hours) and 6,059 recordkeeping records (11,994 hours), reflecting the higher workload for companies and researchers who submit IDE materials.
IDE Application Preparation Time
For investigational device exemption applications and investigational plans (21 CFR 812.20, 812.25, and 812.27), FDA estimates 288 responses annually with an average burden of 80 hours per response, totaling 23,040 hours each year. Other activity-level estimates include items such as 1,500 submissions accepting foreign clinical data averaging 10.25 hours each (15,375 hours).
Use of Leftover Specimens Without Consent
FDA’s guidance (GFI IVD Leftover Specimens April 2006) states the agency does not intend to object to use of leftover human specimens without informed consent if the specimens are not individually identifiable and the study meets the exemption criteria in 21 CFR 812.2(c)(3). This allows investigators to use remnants of specimens collected for routine clinical care in certain IDE studies while protecting subject privacy.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03855 — Determination of Regulatory Review Period for Purposes of Patent Extension; LIMFLOW SYSTEM
The FDA has officially set the review period for the LIMFLOW SYSTEM, a medical device, so its patent can be extended. This affects the company behind LIMFLOW and anyone interested in patent timing or challenges. If you think the dates are wrong or the company wasn’t careful during review, you can speak up by April 27 or August 25, 2026.
Next: 2026-03858 — Combined Notice of Filings #1
The Federal Energy Regulatory Commission got several new filings from energy companies about accounting changes, new energy storage projects, and updates to electric rates. These changes could affect how some companies handle their money and operations, with public comments open until early to mid-March 2026. If you’re involved in energy or just curious, now’s the time to check in and have your say!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in